M R Eccles

Summary

Affiliation: University of Otago
Country: New Zealand

Publications

  1. ncbi Renal-coloboma syndrome: a multi-system developmental disorder caused by PAX2 mutations
    M R Eccles
    Department of Biochemistry, University of Otago, Dunedin, New Zealand
    Clin Genet 56:1-9. 1999
  2. ncbi PAX genes in development and disease: the role of PAX2 in urogenital tract development
    Michael R Eccles
    Department of Pathology, University of Otago, Dunedin, New Zealand
    Int J Dev Biol 46:535-44. 2002
  3. ncbi Genomic structure of the human PAX2 gene
    P Sanyanusin
    Cancer Genetics Laboratory, University of Otago, Dunedin, New Zealand
    Genomics 35:258-61. 1996
  4. ncbi Cloning and characterization of the human PAX2 promoter
    C K Stayner
    Cancer Genetics Laboratory, Department of Biochemistry, University of Otago, Dunedin, New Zealand
    J Biol Chem 273:25472-9. 1998
  5. pmc Comparative in situ hybridization analysis of PAX2, PAX8, and WT1 gene transcription in human fetal kidney and Wilms' tumors
    M R Eccles
    Department of Biochemistry, University of Otago, Dunedin, New Zealand
    Am J Pathol 146:40-5. 1995
  6. ncbi Mutation of PAX2 in two siblings with renal-coloboma syndrome
    P Sanyanusin
    Department of Biochemistry, University of Otago, Dunedin, New Zealand
    Hum Mol Genet 4:2183-4. 1995
  7. ncbi Differential regulation of the human Wilms tumour suppressor gene (WT1) promoter by two isoforms of PAX2
    M J McConnell
    Department of Biochemistry, University of Otago, Dunedin, New Zealand
    Oncogene 14:2689-700. 1997
  8. ncbi Mutation of the PAX2 gene in a family with optic nerve colobomas, renal anomalies and vesicoureteral reflux
    P Sanyanusin
    Department of Biochemistry, University of Otago, Dunedin, New Zealand
    Nat Genet 9:358-64. 1995
  9. ncbi A novel insertional mutation at the third zinc finger coding region of the WT1 gene in Denys-Drash syndrome
    O Ogawa
    Department of Biochemistry, University of Otago, Dunedin, New Zealand
    Hum Mol Genet 2:203-4. 1993
  10. ncbi Imprinting of insulin-like growth factor 2 is modulated during hematopoiesis
    I M Morison
    Cancer Genetics Laboratory, Department of Biochemistry, University of Otago, Dunedin, New Zealand
    Blood 96:3023-8. 2000

Collaborators

Detail Information

Publications29

  1. ncbi Renal-coloboma syndrome: a multi-system developmental disorder caused by PAX2 mutations
    M R Eccles
    Department of Biochemistry, University of Otago, Dunedin, New Zealand
    Clin Genet 56:1-9. 1999
    ..We review here the clinical features of patients with renal-coloboma syndrome and PAX2 mutation. We also review the PAX2 mutations that have been reported to date, and discuss the possible effect of PAX2 mutations on normal development...
  2. ncbi PAX genes in development and disease: the role of PAX2 in urogenital tract development
    Michael R Eccles
    Department of Pathology, University of Otago, Dunedin, New Zealand
    Int J Dev Biol 46:535-44. 2002
    ..We discuss the role of PAX2 in the context of an inhibitory field model of kidney branching morphogenesis and summarize recent progress in this area...
  3. ncbi Genomic structure of the human PAX2 gene
    P Sanyanusin
    Cancer Genetics Laboratory, University of Otago, Dunedin, New Zealand
    Genomics 35:258-61. 1996
    ..Two alternatively spliced exons and a dinuclotide repeat polymorphism were also determined in PAX2. These data will be useful in characterizing the role of PAX2 in human disease...
  4. ncbi Cloning and characterization of the human PAX2 promoter
    C K Stayner
    Cancer Genetics Laboratory, Department of Biochemistry, University of Otago, Dunedin, New Zealand
    J Biol Chem 273:25472-9. 1998
    ..The WT1 tumor suppressor protein, which has previously been shown to repress murine Pax2 expression in vitro, was shown to also repress expression from the human PAX2 promoter...
  5. pmc Comparative in situ hybridization analysis of PAX2, PAX8, and WT1 gene transcription in human fetal kidney and Wilms' tumors
    M R Eccles
    Department of Biochemistry, University of Otago, Dunedin, New Zealand
    Am J Pathol 146:40-5. 1995
    ..It is unlikely that both PAX2 and PAX8 genes would be mutated in WT. However, failure of PAX gene expression to attenuate in WTs may result from mutations involved in the onset of the tumor...
  6. ncbi Mutation of PAX2 in two siblings with renal-coloboma syndrome
    P Sanyanusin
    Department of Biochemistry, University of Otago, Dunedin, New Zealand
    Hum Mol Genet 4:2183-4. 1995
  7. ncbi Differential regulation of the human Wilms tumour suppressor gene (WT1) promoter by two isoforms of PAX2
    M J McConnell
    Department of Biochemistry, University of Otago, Dunedin, New Zealand
    Oncogene 14:2689-700. 1997
    ..A fragment containing the -205/-230 site alone could be transactivated by PAX2. These findings suggest that PAX2 is a tissue-specific modulator of WT1 expression, and is involved in cell growth control via WT1...
  8. ncbi Mutation of the PAX2 gene in a family with optic nerve colobomas, renal anomalies and vesicoureteral reflux
    P Sanyanusin
    Department of Biochemistry, University of Otago, Dunedin, New Zealand
    Nat Genet 9:358-64. 1995
    ..The phenotype resulting from the PAX2 mutation in this family was very similar to abnormalities that have been reported in Krd mutant mice. These data suggest that PAX2 is required for normal kidney and eye development...
  9. ncbi A novel insertional mutation at the third zinc finger coding region of the WT1 gene in Denys-Drash syndrome
    O Ogawa
    Department of Biochemistry, University of Otago, Dunedin, New Zealand
    Hum Mol Genet 2:203-4. 1993
  10. ncbi Imprinting of insulin-like growth factor 2 is modulated during hematopoiesis
    I M Morison
    Cancer Genetics Laboratory, Department of Biochemistry, University of Otago, Dunedin, New Zealand
    Blood 96:3023-8. 2000
    ..These results suggest that transcriptional recognition of the IGF-2 imprint can be modulated during hematopoiesis and may facilitate the development of in vitro model systems to study the transcriptional recognition of a genomic imprint...
  11. ncbi Constitutional relaxation of insulin-like growth factor II gene imprinting associated with Wilms' tumour and gigantism
    O Ogawa
    Department of Biochemistry, University of Otago, Dunedin, New Zealand
    Nat Genet 5:408-12. 1993
    ..These findings suggest that a defect in genomic imprinting can occur constitutionally, leading to growth abnormalities and predisposition to Wilms' tumour...
  12. ncbi Alternative messenger RNA forms and open reading frames within an additional conserved region of the human PAX-2 gene
    T A Ward
    Department of Biochemistry, University of Otago, Dunedin, New Zealand
    Cell Growth Differ 5:1015-21. 1994
    ....
  13. ncbi Cloning of novel Wilms tumor gene (WT1) cDNAs; evidence for antisense transcription of WT1
    M R Eccles
    Department of Biochemistry, University of Otago, Dunedin, New Zealand
    Oncogene 9:2059-63. 1994
    ....
  14. ncbi Human insulin-like growth factor type I and type II receptors are not imprinted
    O Ogawa
    Department of Biochemistry, University of Otago, Dunedin, New Zealand
    Hum Mol Genet 2:2163-5. 1993
    ..That the imprinting of the insulin-like growth factor type II receptor is not conserved between mouse and humans suggests that the physiological role of the IGF2 receptor may differ between these two species...
  15. pmc Structural analysis of the human insulin-like growth factor-II P3 promoter
    A M Raizis
    Biochemistry Department, University of Otago, Dunedin, New Zealand
    Biochem J 289:133-9. 1993
    ..Furthermore, high levels of 5-methylcytosine detected in the P3 promoter of HeLa genomic DNA suggest that IGF-II gene expression may also be influenced by DNA methylation...
  16. ncbi Pax2 gene dosage influences cystogenesis in autosomal dominant polycystic kidney disease
    Cherie Stayner
    Developmental Genetics Laboratory, Department of Pathology, University of Otago, Dunedin, New Zealand
    Hum Mol Genet 15:3520-8. 2006
    ..These data suggest that polycystin-1-deficient tubular epithelia persistently express Pax2 in ADPKD, and that Pax2 or its pathway may be an appropriate target for the development of novel therapies for ADPKD...
  17. ncbi Paired-Box genes are frequently expressed in cancer and often required for cancer cell survival
    Aleksandra Muratovska
    Department of Pathology, Dunedin School of Medicine, University of Otago, PO Box 913, Dunedin, New Zealand
    Oncogene 22:7989-97. 2003
    ..These data suggest that PAX genes are frequently expressed in cancer, and that endogenous PAX gene expression is required for the growth and survival of cancer cells...
  18. ncbi The proline-rich region of mouse p53 influences transactivation and apoptosis but is largely dispensable for these functions
    Sara J Edwards
    Department of Pathology, Dunedin School of Medicine, University of Otago, Box 913, Dunedin, New Zealand
    Oncogene 22:4517-23. 2003
    ..The data are more consistent with the interpretation that the region influences function by altering local protein structure which may affect promoter discrimination...
  19. ncbi Embryonal hyperplasia of Bowman's capsular epithelium in patients with WT1 mutations
    Ryuji Fukuzawa
    Department of Pathology, Keio University School of Medicine, Tokyo, Japan
    Pediatr Nephrol 18:9-13. 2003
    ..Abnormal expression of WT1 and PAX2 in the EHBCE was observed in both patients, supporting our hypothesis. The nephropathy associated with constitutional WT1 mutations might therefore be associated with EHBCE...
  20. pmc A gene expression signature of invasive potential in metastatic melanoma cells
    Aaron R Jeffs
    Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand
    PLoS ONE 4:e8461. 2009
    ..The aim of this study is to identify new prognostic markers and therapeutic targets that might aid clinical cancer diagnosis and management...
  21. ncbi Exclusion of the Wilms tumour gene (WT1) promoter as a site of frequent mutation in Wilms tumour
    G R Grubb
    Department of Pathology, University of Otago Medical School, Dunedin, New Zealand
    Oncogene 10:1677-81. 1995
    ..We therefore conclude that WT1 promoter mutations are unlikely to play an important role in Wilms tumorigenesis...
  22. ncbi Transfection of melanoma cells with antisense PAX3 oligonucleotides additively complements cisplatin-induced cytotoxicity
    Shu Jie He
    Department of Pathology, Dunedin School of Medicine, New Zealand
    Mol Cancer Ther 4:996-1003. 2005
    ..6% (PAX3-AS + cisplatin); M14, 12.6% (1 micromol/L PAX3-AS), 41.5% (40 micromol/L cisplatin), 50.2% (PAX3-AS + cisplatin)]. These data suggest that treatment of melanoma cells with PAX3-AS complements cytotoxicity induced by cisplatin...
  23. doi PAX8 regulates telomerase reverse transcriptase and telomerase RNA component in glioma
    Yu Jen Chen
    Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand
    Cancer Res 68:5724-32. 2008
    ..Additionally, PAX8 small interfering RNA down-regulated hTERT and hTR. Collectively, these results show that PAX8 may have a role in telomerase regulation...
  24. pmc PAX8 promotes tumor cell growth by transcriptionally regulating E2F1 and stabilizing RB protein
    C G Li
    Department of Pathology, Dunedin School of Medicine, University of Otago, New Zealand
    Oncogene 30:4824-34. 2011
    ..Therefore, our results suggest that, in cancer, frequent and persistent expression of PAX8 is required for cell growth control through transcriptional activation of E2F1 expression and upregulation of the RB-E2F1 pathway...
  25. ncbi Expression of the PAX2 gene in human fetal kidney and Wilms' tumor
    M R Eccles
    Department of Biochemistry, University of Otago, Dunedin, New Zealand
    Cell Growth Differ 3:279-89. 1992
    ..By somatic cell hybrid mapping, the PAX2 gene was localized to chromosome 10q22.1-q24.3, although this region has not previously been implicated in Wilms' tumor...
  26. ncbi A novel Cys1638Tyr NC1 domain substitution in alpha5(IV) collagen causes Alport syndrome with late onset renal failure without hearing loss or eye abnormalities
    Jane C Wilson
    Department of Pathology, University of Otago, P O Box 913, Dunedin, New Zealand
    Nephrol Dial Transplant 22:1338-46. 2007
    ..More than 300 sequence variants in type IV collagen have been identified, including alterations in the non-collagenous NC1 domain...
  27. pmc Refined physical map of the human PAX2/HOX11/NFKB2 cancer gene region at 10q24 and relocalization of the HPV6AI1 viral integration site to 14q13.3-q21.1
    Sheryl M Gough
    Cancer Genetics Research Group, Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand
    BMC Genomics 4:9. 2003
    ....
  28. ncbi Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells
    Aleksandra Muratovska
    MRC Dunn Human Nutrition Unit, Wellcome Trust MRC Building, Hills Rd, Cambridge CB2 2XY, UK
    FEBS Lett 558:63-8. 2004
    ....
  29. pmc Disruption of ROBO2 is associated with urinary tract anomalies and confers risk of vesicoureteral reflux
    Weining Lu
    Genetics Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Am J Hum Genet 80:616-32. 2007
    ..Adult heterozygous and mosaic mutant mice with reduced Robo2 gene dosage also exhibit striking CAKUT-VUR phenotypes. Collectively, these results implicate the SLIT-ROBO signaling pathway in the pathogenesis of a subset of human VUR...